| Identification | Back Directory | [Name]
CCT129202 | [CAS]
942947-93-5 | [Synonyms]
CS-407
CCT129202
CCT129202 USP/EP/BP
CCT129202
(CCT-129202
2-(4-(6-Chloro-2-(4-(dimethylamino)phenyl)-1H-imidazo[4,5-b]pyridin-7-yl)piperazin-1-yl)-N-(th
2-[4-[6-Chloro-2-(4-dimethylaminophenyl)-3H-imidazo[4,5-b]pyridin-7-yl]piperazin-1-yl]-N-(thiazol-2-yl)acetamide | [Molecular Formula]
C23H25ClN8OS | [MDL Number]
MFCD26405689 | [MOL File]
942947-93-5.mol | [Molecular Weight]
497.02 |
| Chemical Properties | Back Directory | [density ]
1.427 | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 1 mg/mL (2.01 mM; Need ultrasonic) | [form ]
Powder | [pka]
9.26±0.50(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Biological Activity]
CCT129202 is an ATP-competitive pan-Aurora inhibitor with IC50s of 0.042 μM, 0.198 μM and 0.227 μM for Aurora A, Aurora B and Aurora C, respectively, and has a weaker effect on FGFR3, GSK3β, PDGFRβ, etc. | [in vivo]
CCT129202 at a dose of 100 mg/kg subcutaneously injected HCT116 colon xenografts in athymic mice, after 30 minutes, caused a ~50% decrease in histone H3 phosphorylation, and after 9 days of treatment, significantly inhibited tumor growth, compared with the control group , inhibited by 57.7%. | [target]
Aurora A | [storage]
Store at -20°C |
|
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Tel: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
m.is0513.com/ShowSupplierProductsList15748/0.htm |
|